SpecGx LLC announced FDA approval of the 40 mg and 80 mg strengths of the generic version of Oxycontin (oxycodone hydrochloride) on Tuesday. The availability of these higher-dose formulations is expected to expand generic competition in the chronic pain sector, potentially pressuring the remaining branded market share of the long-acting opioid.